GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Kuros Biosciences Ltd (XSWX:KURN) » Definitions » Net Income (Discontinued Operations)

Kuros Biosciences (XSWX:KURN) Net Income (Discontinued Operations) : CHF0.00 Mil (TTM As of Jun. 2024)


View and export this data going back to 2002. Start your Free Trial

What is Kuros Biosciences Net Income (Discontinued Operations)?

Net Income (Discontinued Operations) indicates the net income that a firm brought in from operations that will not be used in future reporting periods. Kuros Biosciences's Net Income (Discontinued Operations) for the six months ended in Jun. 2024 was CHF0.00 Mil. Its Net Income (Discontinued Operations) for the trailing twelve months (TTM) ended in Jun. 2024 was CHF0.00 Mil.

Kuros Biosciences Net Income (Discontinued Operations) Historical Data

The historical data trend for Kuros Biosciences's Net Income (Discontinued Operations) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kuros Biosciences Net Income (Discontinued Operations) Chart

Kuros Biosciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Income (Discontinued Operations)
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Kuros Biosciences Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Net Income (Discontinued Operations) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Kuros Biosciences Net Income (Discontinued Operations) Calculation

Net Income (Discontinued Operations) indicates the net income that a firm brought in from operations that will not be used in future reporting periods.

Net Income (Discontinued Operations) for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was CHF0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kuros Biosciences Net Income (Discontinued Operations) Related Terms

Thank you for viewing the detailed overview of Kuros Biosciences's Net Income (Discontinued Operations) provided by GuruFocus.com. Please click on the following links to see related term pages.

Kuros Biosciences Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Kuros Biosciences Ltd (XSWX:KURN) » Definitions » Net Income (Discontinued Operations)
Comparable Companies
XSWX:MED XSWX:MOVE ABT SYK BSX MDT XTER:SHL SZSE:300760 EW XAMS:PHIA DXCM STE XSWX:SOON ZBH PODD SHSE:688271 LSE:SN. ASX:COH GMED BIO
Traded in Other Exchanges
CSBTF:USA KURNz:UK 0RHR:UK
Address
Wagistrasse 25, Schlieren, Zurich, CHE, 8952
Website
https://www.kurosbio.com
Kuros Biosciences Ltd is a Swiss-based biopharmaceutical company focused on the development of innovative products for tissue repair and bone regeneration. It operates through the following segments: Medical devices, Pharmaceuticals and Legacy portfolio. The Medical devices segment includes products such as MagnetOs and Attrax. The Pharmaceuticals segment includes products such as Fibrin-PTH, a drug-biologic combination that promotes targeted and controlled bone formation through the induction of osteoprogenitor cell differentiation, enhancement, of osteoblast proliferation and increasing the lifespan of bone-forming cells. The Legacy portfolio segment includes all other products that do not belong to the group's core business strategy.

Kuros Biosciences Headlines

No Headlines